The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response
Open accessAbstract
Background Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse. Methods We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies. Results BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (OR = 0.12, p = 0.042). Conclusions Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Solid organ transplant recipients on MMF-containing regimens were at risk of a negative humoral response to the BNT162b2 mRNA vaccine.
“Consistently, solid organ transplant recipients treated with regimens including MMF were at risk of a negative humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine.43 44”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“4% reported at least one systemic reaction.(1) In the nontransplant population, the BNT162b2 vaccine elicits antibody responses against the RBD, and plasma binding and neutralizing activity of the vaccine against SARS-CoV-2 has been demonstrated.”
Flagged first, then by citations
Research works printed but not linked: 8
- Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 · DOI · Paper page
- Boyarsky, 2021, Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients, JAMA, 325, 1784, 10.1001/jama.2021.4385 · DOI
- Boyarsky, 2021, Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients, Transplantation, 105, e56, 10.1097/TP.0000000000003654 · DOI
- Dieterle, 2020, A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition, Cell Host Microbe, 28, 486, 10.1016/j.chom.2020.06.020 · DOI
- Wang, 2021, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants, Nature, 592, 616, 10.1038/s41586-021-03324-6 · DOI · Paper page
- Hellerstein, 2020, What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2?, Vaccine X, 6, 10.1016/j.jvacx.2020.100076 · DOI
- Natori, 2018, A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients, Clin Infect Dis, 66, 1698, 10.1093/cid/cix1082 · DOI
- Rentenaar, 2002, Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo, Kidney Int, 62, 319, 10.1046/j.1523-1755.2002.00425.x · DOI
Metadata
- Authors
- Peled, Y., Ram, E., Lavee, J., Sternik, L., Segev, A., Wieder-Finesod, A., Mandelboim, M., Indenbaum, V., Levy, I., Raanani, E., Lustig, Y., & Rahav, G.
- Affiliations
- Tel Aviv University (IL)
- Israel Ministry of Health (IL)
- Corresponding author
- Peled, Yael
- ORCID
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 40
- Issue
- 8
- Pages
- 759-762
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8058049
- OpenAlex
- W3154374447
- Cited by
- 126
- References
- 1
- Citations by year
- 2025: 5 · 2024: 7 · 2023: 20 · 2022: 54 · 2021: 40
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- BNT162b2, heart transplant recipients, COVID-19 vaccination, immunosuppression, mycophenolic acid, antibody response, neutralizing antibodies, receptor-binding domain IgG, vaccine safety, adverse events, allograft rejection, immunocompromised patients
- MeSH terms
- COVID-19, COVID-19 Vaccines, BNT162 Vaccine, Aged, Antibody Formation, Female, Humans, Immunosuppression Therapy, Male, Middle Aged, Postoperative Complications, Prospective Studies, Heart Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
